A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors

PURPOSE: To evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics/pharmacodynamics, and early clinical activity of ixabepilone given either weekly or every three weeks in combination with daily sunitinib in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Eligible patients rec...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Montero, Alberto J., Kwon, Deukwoo, Flores, Aurea, Kovacs, Krisztina, Trent, Jonathan, Benedetto, Pasquale, Rocha-Lima, Caio, Merchan, Jaime R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4930738/
https://ncbi.nlm.nih.gov/pubmed/26864210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2184
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi